Riociguat
|
- ₹0
- Product name: Riociguat
- CAS: 625115-55-1
- MF: C20H19FN8O2
- MW: 422.42
- EINECS:641-755-1
- MDL Number:MFCD19443708
- Synonyms:Riociguat;N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methylcarbamic acid methyl ester;Bay 63-2521;Carbamic acid, (4,6-diamino-2-(1-((2-fluorophenyl)methyl)-1H-pyrazolo(3,4-B)pyridin-3-yl)-5-pyrimidinyl)methyl-, methyl ester;Riociguat (BAY 63-2521);Bay63-2521,Riociguat;[4,6-DiaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]MethylcarbaMic acid Methyl ester;Methyl (4,6-diaMino-2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)pyriMidin-5-yl)(Methyl)carbaMate
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|
Properties
Melting point :247-251°C (dec.)
Boiling point :567.2±50.0 °C(Predicted)
Density :1.51
storage temp. :Refrigerator
solubility :DMSO (Slightly, Heated), Methanol (Slightly, Heated)
pka :1.51±0.50(Predicted)
form :Solid
color :Off-White to Orange
InChI :InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
InChIKey :WXXSNCNJFUAIDG-UHFFFAOYSA-N
SMILES :C(OC)(=O)N(C1=C(N)N=C(C2C3=CC=CN=C3N(CC3=CC=CC=C3F)N=2)N=C1N)C
Boiling point :567.2±50.0 °C(Predicted)
Density :1.51
storage temp. :Refrigerator
solubility :DMSO (Slightly, Heated), Methanol (Slightly, Heated)
pka :1.51±0.50(Predicted)
form :Solid
color :Off-White to Orange
InChI :InChI=1S/C20H19FN8O2/c1-28(20(30)31-2)15-16(22)25-18(26-17(15)23)14-12-7-5-9-24-19(12)29(27-14)10-11-6-3-4-8-13(11)21/h3-9H,10H2,1-2H3,(H4,22,23,25,26)
InChIKey :WXXSNCNJFUAIDG-UHFFFAOYSA-N
SMILES :C(OC)(=O)N(C1=C(N)N=C(C2C3=CC=CN=C3N(CC3=CC=CC=C3F)N=2)N=C1N)C
Safety Information
| Symbol(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | ||||||||||||||
| Hazard statements: |
|
||||||||||||||
| Precautionary statements: |
|
Description
In September 2013, Health Canada approved riociguat (also referred to as BAY 63-2521), for the treatment of patients with chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH and for the treatment of adults with pulmonary arterial hypertension (PAH). Riociguat has a dual mode of action and works by (a) sensitizing sGC to the body’s NO by stabilizing NO–sGC binding and (b) an NO-independent, direct stimulation of sGC via a different binding site. This process restores the NO–sGC–cGMP pathway and leads to increased generation of cGMP with subsequent vasodilation.Headache, dizziness, dyspepsia/gastritis, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, and constipation were the most common adverse events ( 3%) observed during riociguat clinical trials. Riociguat comes with a black box warning for embryo-fetal toxicity.
More related product prices
Posaconazole Entacapone 1-(2-Fluoro-benzyl)-1H-py... 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine Bosentan hydrate Ambrisentan macitentan Fondaparinux sodium Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate K115 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethyl-phenyl]amino]pyrimidin-2-yl]amino]benzonitrileRelated product price
- Posaconazole
₹3600-53854.38 - Entacapone
₹7707.4-25958.35 - Bosentan hydrate
₹2800-43613.93